In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 401 to 424 of 424

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]	Technology appraisal guidance	TBC
Vamorolone for treating Duchenne muscular dystrophy [ID4024]	Technology appraisal guidance	TBC
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372	Technology appraisal guidance	TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]	Technology appraisal guidance	TBC
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565	Technology appraisal guidance	TBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]	Technology appraisal guidance	TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]	Technology appraisal guidance	TBC
Venglustat for treating gangliosidoses in people 2 years and over ID 6358	Technology appraisal guidance	TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]	Technology appraisal guidance	TBC
Violence and Aggression: short-term management in mental health, health and community settings	NICE guideline	TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]	Technology appraisal guidance	TBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over ID6407	Technology appraisal guidance	TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]	Highly specialised technology	TBC
Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy ID6470	Technology appraisal guidance	TBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]	Technology appraisal guidance	22 November 2017
Women's and reproductive health guidelines	NICE guideline	TBC
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]	Technology appraisal guidance	TBC
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]	Technology appraisal guidance	20 August 2025
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]	Technology appraisal guidance	TBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]	Technology appraisal guidance	TBC
Zio XT for detecting cardiac arrhythmias	Medical technologies guidance	TBC
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]	Technology appraisal guidance	TBC
Zuranolone for treating severe postnatal depression ID6431	Technology appraisal guidance	TBC

Results per page

10
25
50
All